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Summary
Based on breast cancer families with multiple and/or
early-onset cases, estimates of the lifetime risk of breast
cancer in carriers of BRCA1 or BRCA2 mutations may
be as high as 85%. The risk for individuals not selected
for family history or other risk factors is un-
certain. We determined the frequency of the common
BRCA1 (185delAG and 5382insC) and BRCA2
(6174delT) mutations in a series of 268 anonymousAsh-
kenazi Jewish women with breast cancer, regardless of
family history or age at onset. DNA was analyzed for
the three mutations by allele-specific oligonucleotide hy-
bridization. Eight patients (3.0%, 95% confidence in-
terval [CI] 1.5%–5.8%) were heterozygous for the
185delAGmutation, two (0.75%, 95%CI 0.20–2.7) for
the 5382insC mutation, and eight (3.0%, 95% CI
1.5–5.8) for the 6174delT mutation. The lifetime risk
for breast cancer in Ashkenazi Jewish carriers of the
BRCA1 185delAG or BRCA2 6174delT mutations was
calculated to be 36%, approximately three times the
overall risk for the general population (relative risk 2.9,
95% CI 1.5–5.8). For the 5382insC mutation, because
of the low number of carriers found, further studies are
necessary. The results differ markedly from previous es-
timates based on high-risk breast cancer families and are
consistent with lower estimates derived from a recent
population-based study in the Baltimore area. Thus, pre-
symptomatic screening and counseling for these com-
mon mutations in Ashkenazi Jewish women not selected
for family history of breast cancer should be reconsid-
ered until the risk associated with these mutations is
firmly established, especially since early diagnostic and
preventive-treatment modalities are limited.
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Introduction
The findings of common mutations in the BRCA1
(185delAG) and BRCA2 (6174delT) genes in breast can-
cer families of Ashkenazi Jewish descent and of the high
frequency of these mutations (∼1%–1.5% each) among
Ashkenazi Jewish individuals (Simard et al. 1994; Tonin
et al. 1995; FitzGerald et al. 1996; Neuhausen et al
1996; Oddoux et al. 1996; Offit et al. 1996; Roa et al.
1996; Struewing et al. 1995; Tavtigian et al. 1996) have
generated intense discussion concerning the relative eth-
ical and medical merits and/or consequences of pro-
spective screening in this population. Although such
screening is now feasible, the risks and benefits of this
approach remain uncertain because the lifetime risk of
developing breast cancer among carriers of these mu-
tations is unknown, particularly among women without
a family history of breast cancer. Moreover, the absence
of a mutation may lead to a false sense of reassurance.
A high (92%) lifetime risk associated with breast can-
cer–predisposing genes, based on segregation analysis in
families (age range 20–54 years), has been estimated
(Claus et al. 1991), and a similarly high (85%) risk of
the common BRCA1 and BRCA2 mutations has been
reported in families with multiple affected first- and sec-
ond-degree relatives with early-onset disease (Ford et al.
1994; Wooster et al. 1994; Easton et al. 1995; Stratton
1996; Shattuck-Eidens et al. 1997). However, relative
risks (RRs) of the common BRCA1 and BRCA2 mu-
tations in Ashkenazi Jewish families not selected for ei-
ther the number of affected members or age at onset of
breast cancer are uncertain; this precludes the ability to
reliably inform carriers of their risk.
Previous studies determined the lifetime risk of the
common BRCA1 185delAG and BRCA2 6174delT mu-
tations in patients with early onset and/or extensive fam-
ily history. It was estimated that, in the Ashkenazi Jewish
population, 16% (Struewing et al. 1995), 20% (Fitz-
Gerald et al. 1996), or 22% (Offit et al. 1996) of breast
cancer cases diagnosed at ages !50, !40, and !42 years,
respectively, were attributable to the 185delAGmutation
and that the RR of 185delAG carriers to develop breast
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cancer at age !40 years was 27 times that of noncarriers
(FitzGerald et al. 1996). Moreover, it was estimated that
the lifetime risk (at age X85 years) of carriers to develop
breast cancer was ∼85% (Ford et al. 1994; Easton et al.
1995). These studies provided estimates of age-related
penetrance and attributable risks in early-onset patients
or in patients with strong family histories. Recently, a
population-based study of Ashkenazi Jewish volunteers
in the Baltimore area estimated that the risk of breast
cancer, by age 70 years, for carriers of one of the three
common BRCA1 and BRCA2 mutations was 56%, sig-
nificantly lower than previous estimates based on data
from high-risk families (Struewing et al. 1997). How-
ever, estimates of risk from population-based studies of
volunteers may introduce a selective bias toward those
with a positive family history, leading to overestimations
(Abeliovich et al. 1997; Struewing et al. 1997).
To assess the contributions of the common BRCA1
(185delAG and 5382insC) and BRCA2 (6174delT) mu-
tations to the incidence of breast cancer in a breast can-
cer population of Ashkenazi Jewish descent, a study was
undertaken to determine the frequency of these muta-
tions in a consecutive series of 268 Ashkenazi Jewish
female breast cancer patients who were not selected for
family history or age at diagnosis. In addition, the pop-
ulation frequencies of the three common BRCA1 and
BRCA2 mutations were determined in 1,715 Ashkenazi
Jewish individuals from the same geographic area who
requested prenatal carrier testing for genetic diseases that
are more frequent among Ashkenazi Jews.
Subjects and Methods
Collection of Samples in the Ashkenazi Jewish
Population
DNA samples from Ashkenazi Jewish men and
women from the New York metropolitan area who were
referred for prenatal carrier testing were archived, with
informed consent, for use in other research studies. No
identifiers were retained, and the samples were anony-
mous to investigators. The average age of this popula-
tion was 35 years. Previous family- and cancer-history
analysis did not reveal a personal history of breast cancer
in any of these control individuals.
Collection of Samples from Ashkenazi Jewish Women
with Breast Cancer
Clinical, family-history, and demographic information
for a consecutive series of 298 self-identified Ashkenazi
Jewish women with intraductal or infiltrating breast car-
cinoma who had had a biopsy, excision, or mastectomy
at the Mount Sinai Medical Center, between 1986 and
1995, was entered into a database. Tissue blocks and
stained slides of the primary breast carcinoma were ob-
tained from 285 patients, and the histological features
of the cancers were evaluated by two pathologists (I.J.B.
and M.M.W.) and recorded in the database. After the
tissue blocks were obtained, the original patient iden-
tifiers were removed, numerical identifierswere assigned,
and the records and tissue blocks were distinguished by
the new identifying numbers. Our institutional ethicist,
acting as a third-party liaison, then assumed responsi-
bility for maintaining the database. DNA results were
communicated to the ethicist, who then entered the
anonymous information into the database. In this way,
all investigators were blinded to the combined data.
DNA Isolation
DNA was extracted from single 15-mm sections from
paraffin-embedded archival tissue blocks (lymph node
or breast) according to the dewaxing–Chelex-boiling
method (Sepp et al. 1994). Amplifiable DNA was ob-
tained from 268 of the 285 tissue blocks. Family his-
tories regarding breast cancer were available in 262 of
these cases.
Detection of the BRCA1 185delAG and 5382insC and
BRCA2 6174delT Mutations by Allele-Specific
Oligonucleotide (ASO) Hybridization
Triplex PCR was performed to amplify fragments of
250, 230, and 87 bp for the 185delAG, 5382insC, and
6174delT mutations, respectively. PCR primers for the
185delAG (Friedman et al. 1994), 5382insC (Gayther
et al. 1996), and 6174delT (Neuhausen et al. 1996) mu-
tations were “tagged” by a universal primer sequence,
at the 5′ end, to facilitate simultaneous amplification
(Shuber et al. 1995). The reaction contained 1 mM, 0.5
mM, and 0.75 mM of both primers for the 185delAG,
5382insC, and 6174delT mutations, respectively; 300
mM each dNTP; 2.5 mM MgCl2; 1 # PCR buffer (Per-
kin-Elmer); 5 UTaq polymerase (Perkin-Elmer); and∼80
ng genomic DNA in a 50-ml reaction volume. PCR pa-
rameters were the same as those described by Shuber et
al. (1995), except for a 20-s extension time.
For the detection of each mutation, 3-ml aliquots of
the PCR products were blotted onto replicate mem-
branes (8 # 12 cm) in a 96-well format by use of an
automated pipetting workstation (Biomek 2000; Beck-
man Instruments). ASOs for the 185delAG (Struewing
et al. 1996) and 5382insC mutations have been de-
scribed elsewhere (Friedman et al. 1995). For the
6174delT mutation, the ASOs were wild type, 5′-ACA
GCA AGT GGA AAA TC-3′, or mutation specific, 5′-
ACA GCA AGG GAA AAT CT-3′. The membranes were
hybridized for 1 h at 42C with ∼106 cpm of each end-
labeled probe/ml, to detect the 185delAG and 6174delT
mutations. For the 5382insC mutation, competitive hy-
bridization was performed by addition of a 10-molar
excess of the cold mutant and wild-type oligonucleotides
along with the labeled wild-type and mutant probes,
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Figure 1 A representative dot-blot hybridization of the PCR
products hybridized by allele-specific oligonucleotides complementary
to the normal allele (left panel) and to the 6174delT mutant allele
(right panel). A positive control is shown in the upper-right corner,
preceded by a DNA blank; two patients were heterozygous for the
mutation. Amplification failures were noted.
Table 1
Mutation-Carrier Frequencies (F and CBC) in Ashkenazi Jews
PRENATAL SCREENING
GROUP
( )n  1,715
BREAST CANCER
PATIENTS
( )n  268
MUTATION
No. (%)
Positive 95% CI
No. (%)
Positive 95% CI
185delAG 18 (1.05) .7–1.8 8 (2.99) 1.5–5.8
6174delT 18 (1.05) .7–1.8 8 (2.99) 1.5–5.8
5382insC 2 (.12) 0–.46 2 (.75) .20–2.7
respectively. The membranes were then washed sequen-
tially in 6 # SSC for 10 min at room temperature and
in 6 # SSC for 10 min at 45C, followed by a wash at
stringency (0.5 # SSC/0.1% SDS for 10 min at 45C),
and were then exposed to autoradiography (fig. 1). All
positive results were confirmed by repeated analysis; in
addition, some randomly selected positive cases were
confirmed by DNA sequence analysis.
Statistical Analysis
The frequencies of mutations in the general popula-
tion and in the breast cancer group were calculated from
numbers of individuals in each group. The 95% confi-
dence intervals (CIs) were determined by use of a bi-
nomial exact test. General population frequencies were
compared with previous literature reports by use of
Fisher’s exact test. Odds ratios were estimated by use of
the Mantel-Haentzel test. From SEER data (186,000
newly diagnosed breast cancers per year in the United
States; Parker et al. 1997), the lifetime risk of breast
cancer in the general population is calculated to be
12.5% (1 in 8), with the assumption of a life span of
85 years. The lifetime risk of breast cancer for the Ash-
kenazi Jewish population is not significantly different
from that for the general population (Egan et al. 1996).
Carrier risk (RC), RR, and attributable risk (AR)
values were calculated by use of the following for-
mulas: , , andR  C R /F RR  R /R AR(%) C BC G C G
, where CBC is the proportion of100C (RR 1)/RRBC
mutation carriers among patients with breast cancer ob-
served in the present study, RG is the risk of breast cancer
in the general population (.125), and F is the carrier
frequency in the Ashkenazi Jewish population observed
in the present study.
Results
Frequency of the Common BRCA1 and BRCA2
Mutations in the Ashkenazi Jewish Population
Among 1,715 anonymous DNA samples from a series
of Ashkenazi Jewish men and women referred for pre-
natal carrier testing for Jewish genetic diseases, analysis
for the 185delAG, 5382insC, and 6174delT mutations
revealed Fs of 1.05%, 0.12%, and 1.05%, respectively
(table 1). No individual carried more than one mutation.
Thus, 2.22% of the individuals examined were hetero-
zygous for one of the three mutations. These values for
F were not significantly different from those previously
reported for 185delAG (Roa et al. 1996; Struewing et
al. 1996, 1997), 5382insC (Roa et al. 1996; Struewing
et al. 1997), or 6174delT (Oddoux et al. 1996; Roa et
al. 1996; Struewing et al. 1997), and the Fs obtained
for each mutation by combining the data from the five
studies were 0.92, 0.26, and 1.20, respectively (table 2).
Frequency of the Common BRCA1 and BRCA2
Mutations in Ashkenazi Jewish Women with Breast
Cancer
PCR-amplifiable DNA was obtained from a series of
268 archived pathological tissues fromAshkenazi Jewish
female breast cancer patients who were not selected for
age or family history. The average age at diagnosis was
58.7 years (range 35–90 years, SD 12.9 years); 19
women were age !42 years, 78 women were age 42–50
years, and 171 were age 150 years at diagnosis. Of the
262 women for whom family-history information was
available, 162 reported negative family histories of
breast cancer. A 36-year-old patient and a 48-year-old
patient had both breast and ovarian cancer, and 11 pa-
tients had bilateral breast cancer. As shown in table 3,
18% of patients reported having a first-degree relative
with breast cancer.
Eight (3.0%) of the 268 women studied were found
to carry the 185delAG mutation, two (0.75%) carried
the 5382insC mutation, and eight (3.0%) carried the
6174delT mutation (table 1). The family history, clinical
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Table 2
Reported Carrier Frequencies for the Common BRCA1 and BRCA2 Mutations in the Ashkenazi Jewish Population
STUDY
185delAG 6174delT 5382insC
No. of
Carriers
No. of
People
Screened
Carrier
Frequency
(%)
No. of
Carriers
No. of
People
Screened
Carrier
Frequency
(%)
No. of
Carriers
No. of
People
Screened
Carrier
Frequency
(%)
Struewing et al. (1995) 8 858 .93 ) ) ) ) ) )
Roa et al. (1996) 34 3,108 1.09 47 3,085 1.5 4 3,116 .13
Oddoux et al. (1996) ) ) ) 12 1,255 .96 ) ) )
Struewing et al. (1997) 41 5,318 .77 59 5,318 1.11 20 5,318 .38
Present study 18 1,715 1.05 18 1,715 1.05 2 1,715 .12
Overall 101 10,999 .92 136 11,373 1.20 26 10,149 .26
Table 3
Family History of Breast Cancer among Ashkenazi Jewish Breast
Cancer Patients and Mutation Carriers
No. of Affected Relatives,
by Degree
No. of
Patients
No. of
Carriers
2 first 4 )
1 first , 2 second 2 )
1 first, 1 second, 1 third 3 1
1 first, 1 second 7 1
1 first, 1 third 5 1
1 first 26 )
2 second, 2 third 1 )
2 second 2 1
1 second, 1 third 6 1
1 second 34 2
2 third 1 )
1 third 19 1
Subtotal 110 8
Negative family history 152 10
Family history unavailable 6 )
Total 268 18
history, and pathological features of each of the 18 mu-
tation carriers are given in table 4. Ten of the 18 mu-
tation carriers were without a family history of breast
cancer. Unexpectedly, only 3 of the 19 patients age !42
years carried a mutation, even though 11 of the re-
maining 16 patients had positive family histories of
breast cancer. Five carriers were identified in the 42–50-
year age group, and 10 were in the 150-year age group
(table 5). A mutation was detected in 1 of the 11 patients
who had bilateral cancer. Only 3 of the 19 patients who
had at least two affected first- or second-degree relatives
were found to carry a mutation. Notably, two patients
who carried the 6174delT mutation had two affected
relatives but developed breast cancer at ages 60 and 74
years, respectively.
The histopathological evaluation showed infiltrating
ductal carcinoma in each of the 18 cases, with distinctive
features in some. The majority (13 of 18) were poorly
differentiated, as scored by modified Bloom-Scarf-Rich-
ardson criteria. Seven patients had metastatic carcinoma
in axillary lymph nodes, 10 had negative lymph node
findings, and 1 patient did not undergo axillary dissec-
tion. No distinctive histopathological characteristics
were consistently observed in the tumors of carriers as
compared with those of noncarriers.
Based on the observed F values and an assumed life-
time breast cancer risk of 85%, the expected number of
both the BRCA1 185delAG and the BRCA2 6174delT
mutation carriers among the 268 breast cancer patients
was 18.0. However, for both mutations, only eight car-
riers were observed ( ; ). For the2x  6.16 P  .013
5382insC mutation, the expected number of carriers
(2.1) was similar to what was found (2). However, the
wide CI (95% CI .002–.0268) for the proportion of
5382insC carriers among the patients, which is due to
the low population frequency, indicated that further
studies are required for risk estimation for this mutation
(table 1).
Discussion
Since the risk of breast cancer associated with the in-
heritance of the common BRCA1 and BRCA2mutations
in a population-based sample of Ashkenazi Jewish
women is uncertain, the frequency of these mutations
was determined in a series of Ashkenazi Jewish female
breast cancer patients who were not selected for family
history or age at onset. Of the 268 women studied, 42%
had first-, second-, or third-degree relatives with breast
cancer, but only 5 women had as many as three affected
first- or second-degree relatives. Therefore, these women
would not generally be classified as high risk (Hoskins
et al. 1995), and the available risk estimates would not
apply. The present study provided information on the
frequency of the common BRCA1 185delAG and
BRCA2 6174delT mutations in a group of Ashkenazi
Jewish women considered to be at low or moderate risk
because of the absence of a strong family history. These
data permit the estimation of lifetime risks of breast
cancer, which may be used for genetic counseling and
decision making.
The RR of breast cancer among mutation carriers,
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Table 4
Age at Onset and Family History of Breast Cancer among 18
Ashkenazi Jewish Carriers of Common BRCA1 and BRCA2
Mutations
Age at Onset
(years) Family Historya
185delAG:
44  (aunt, cousin)
67  (ovarian cancer)
36  (ovarian cancer)
56  (aunt, cousin)
44  (aunt)
68 
56, 67  (bilateral)
75 
6174delT:
60  (mother [60], cousin)
35 
40 
42 
74  (sister, GM)
56  (GM, cousin)
63  (bilateral)
46  (mother [64], maternal GM [36],
maternal great GM)
5382insC:
80 
49  (GM, aunt)
a A plus sign () indicates a positive family history, and a
minus sign () indicates a negative family history. GM grand-
mother. Additional information regarding cancer status or af-
fected family members (with age at onset, in years) appears in
parentheses.
Table 5
Germ-Line 185delAG, 5382insC, or 6174delT Mutations among
Ashkenazi Jewish Breast Cancer Patients Stratified by Age at Onset
Age at Onset
(years)
No. of Patients
Studied
No. (%) of Mutation
Carriers
!42 19 3 (16)
42–50 78 5 (6.4)
150 171 10 (5.8)
Overall 268 18 (6.7)
compared with noncarriers, was 2.90 (95% CI
1.46–5.78) for the 185delAG and 6174delT mutations,
corresponding to a lifetime (age 85 years) risk of 36%
for each mutation (table 6). For the 5382insC mutation,
which has a population frequency of ∼0.26%, a more
extensive study must be performed. The finding of an
equally low lifetime-risk value for the 6174delT muta-
tion in this population-based setting is in contrast to
previous speculations based on data obtained from high-
risk families, which indicated that the penetrance of the
6174delT mutation was lower than that of the
185delAG mutation (Roa et al. 1996; Tonin et al. 1996).
The present study was conducted in a consecutive ran-
dom series of 268 Ashkenazi Jewish breast cancer pa-
tients and thus eliminated the bias of ascertainment that
may be reflected in the population-based study con-
ducted by Struewing et al. (1997). In that study, 30%
of the 288 survivors of breast cancer reported an affected
first-degree relative, as opposed to 18% in the present
study, which may be a more representative patient sam-
ple. However, the results of these two studies indicate
that the RC for these recurrent mutations is probably
significantly less than previous estimates based on high-
risk families.
For women at low-to-moderate risk for breast cancer,
informed choices regarding prospective screening require
information concerning the lifetime risks of breast cancer
among women identified as mutation carriers. Clearly,
the predictive value of positive and negative test results
must be determined for informed decision making and
genetic counseling. The predictive value of a negative
test is 87.5%, whereas the predictive value of a positive
test result is equal to RC. Data obtained from this pop-
ulation indicate that the positive predictive value is 36%
for both the 185delAG and the 6174delT mutations. In
view of the low predictive value of positive mutation
testing without strong family histories, together with the
lack of effective primary and secondary breast can-
cer–prevention measures (reviewed by Stratton 1996),
screening and counseling strategies may be best focused
on high-risk women. Because of sample-size considera-
tions, more extensive studies of nonselected groups of
Ashkenazi Jewish breast cancer patients are necessary to
confirm these results. Such findings would imply that,
when presymptomatic testing for the common BRCA1
and BRCA2 mutations in the Ashkenazi Jewish popu-
lation is considered, a clear distinction should be made
between high-risk women (those with a strong family
history and/or early-onset breast cancer) and women
with low or moderate risk. In addition, more studies are
necessary to estimate the breast cancer risk in individuals
who carry the 5382insC mutation. Preliminary results
from this study and others (Struewing et al. 1997) sug-
gest that the lifetime risk associated with this mutation
may be higher than the risks associated with the
185delAG or 6174delT mutations.
BRCA1 mutations have been associated with high-
grade infiltrating carcinoma, as measured by its histo-
logical components of high proliferative activity, nuclear
pleomorphism, and decreased tubule formation (Bignon
et al. 1995; Eisinger et al. 1996; Marcus et al. 1996),
as well as an excess of tumors with medullary features;
however, survival in two reports was paradoxically not
worsened despite the adverse prognostic features (Big-
non et al. 1995; Marcus et al. 1996). BRCA2 mutations
have reportedly been associated with tubulo-lobular
group histology and a similarly favorable prognosis (Big-
non et al. 1995). Although our study lacks sufficient
numbers of mutation-positive cases to draw definitive
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Table 6
RC, RR, and AR Values Calculated from CBC and F
Mutation RC RR (95% CI) AR
185delAG .36 2.90 (1.46 –5.78) 1.95%
6174delT .36 2.90 (1.46–5.78) 1.95%
5382insC .81 6.44 (1.72–23.6) .63%
NOTE.—A general population risk of .125 to develop breast cancer
is assumed. See text for formulas used for these calculations.
conclusions, we found that both BRCA1 and BRCA2
mutation cases were associated with poorly differenti-
ated tumors. In contrast to other authors, we found no
excess of medullary features or tubulo-lobular histology
in either group. Long-term follow-up information was
not available because of the blinded nature of the study.
Clearly the pathological characteristics and clinical out-
come of these lesions are of great importance, deserving
further investigations.
Although we could not show a correlation between
the presence of the 185delAG or 6174delT mutations
and clinical/pathological characteristics, the potential to
evaluate genotype-phenotype relationships in groups of
patients with the same mutation may yield important
information regarding prognosis and possible treatment
options. In addition, the lifetime risk values of 36% for
both the 185delAG and 6174delT mutations indicate
that other genetic or environmental factors interact with
these mutant genes either to induce cancer or, alterna-
tively, to protect carriers from developing breast cancer.
The Ashkenazi Jewish population should provide an in-
formed, cooperative, and relatively homogeneous pop-
ulation for further studies of the factors that influence
the expression of breast cancer.
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